Search
for
Sort by
Research 121–150 of 1000+
- Treatments for alopecia areata: a network meta-analysis
- Reporting on Adverse Clinical Events
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment
- The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial
- Ethinylestradiol/Chlormadinone Acetate
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- Dutasteride
- Janus Kinase Inhibitors for Alopecia Areata
- Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo‐controlled, double‐blind, noninferiority study
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
- Abstract PS1-01-19: Exploratory Study on the Efficacy and Safety of Combined Scalp Cooling and HairRepro MEDIα for Chemotherapy-Induced Alopecia in Japanese Breast Cancer Patients
- Systematic review of low-level laser therapy for adult androgenic alopecia
- Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open‐Label Single‐Arm Clinical Trial
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
- 022 Randomized, double-blind, placebo-controlled, single-centre, phase I safety study of intradermal injections of autologous fibroblasts isolated from the non-bulbar dermal sheath of the hair follicle to treat skin aging
- Development of PEGylated Liposomes
- Veterinary Pharmacology
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Factors predicting response to oral methylprednisolone tapering treatment in alopecia areata: A retrospective study
- Combined Effect of Microneedling and Platelet-Rich Plasma for the Treatment of Acne Scars: A Meta-Analysis
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital